✦ LIBER ✦

M1795 Pegylated Interferon Alfa-2a Plus Ribavirin in Chronic Hepatitis C Patients with Genotype 6

✍ Scribed by Pham, Thuy T.; Ho, Dat T.

Book ID: 121902336
Publisher: Elsevier Science
Year: 2009
Tongue: English
Weight: 63 KB
Volume: 136
Category: Article
ISSN: 0016-5085
DOI: 10.1016/S0016-5085(09)63869-5

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Effect of Ribavirin in Genotype 1 Patien

Effect of Ribavirin in Genotype 1 Patients With Hepatitis C Responding to Pegylated Interferon Alfa-2a Plus Ribavirin

✍ Jean–Pierre Bronowicki; Denis Ouzan; Tarik Asselah; Hervé Desmorat; Jean–Pierre 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 378 KB

Response to pegylated interferon alfa-2a

Response to pegylated interferon alfa-2a and ribavirin in chronic hepatitis C genotype 4

✍ Hesham El Makhzangy; Gamal Esmat; Mohamed Said; Maissa ElRaziky; Soheir Shouman; 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 91 KB

## Abstract The safety and efficacy of pegylated interferon (PEG‐IFN) alfa‐2a and ribavirin were studied among patients treated for genotype 4 chronic hepatitis C. Ninety‐five patients with chronic hepatitis C genotype 4 were treated with PEG‐IFN alfa‐2a (180 µg/week) plus ribavirin (≥11 mg/kg/day)

Randomized controlled trial of pegylated

Randomized controlled trial of pegylated interferon-alfa 2a and ribavirin in treatment-naive chronic hepatitis C genotype 6

✍ Khoa D. Lam; Huy N. Trinh; Son T. Do; Thuan T. Nguyen; Ruel T. Garcia; Tuan Nguy 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 246 KB 👁 2 views

Hepatitis C virus (HCV) genotype is an important criteria in determining duration of therapy and predictor of sustained virologic response (SVR) to pegylated interferon (PEG IFN) and ribavirin (RBV) therapy. Optimal duration of therapy for patients with HCV genotype 6 is not known. We conducted a mu

Peginterferon Alfa-2a plus Ribavirin ver

Peginterferon Alfa-2a plus Ribavirin versus Interferon Alfa-2a plus Ribavirin for Chronic Hepatitis C in HIV-Coinfected Persons

✍ Chung, Raymond T.; Andersen, Janet; Volberding, Paul; Robbins, Gregory K.; Liu, 📂 Article 📅 2004 🏛 Massachusetts Medical Society 🌐 English ⚖ 110 KB

Efficacy and safety of ribavirin plus pe

Efficacy and safety of ribavirin plus pegylated interferon alfa in geriatric patients with chronic hepatitis C

✍ Hu, C.-C.; Lin, C.-L.; Kuo, Y.-L.; Chien, C.-H.; Chen, S.-W.; Yen, C.-L.; Lin, C 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 138 KB

Pegylated interferon alpha-2b plus ribav

Pegylated interferon alpha-2b plus ribavirin in patients with genotype 4 chronic hepatitis C: Some issues

✍ Ming-Lung Yu; Chia-Yen Dai; Jee-Fu Huang; Ming-Yen Hsieh; Wan-Long Chuang 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 63 KB 👁 2 views

accurate representation of the data is given in Table 1. 7. The major conclusion of this paper was that monitoring hepatitis C virus RNA levels and varying the duration of therapy can save resources without sacrificing rates of SVR. The authors used the Blackwelder test to test the noninferiority of